

Correction: A novel PI3K inhibitor PIK-C98 displays potent preclinical activity against multiple myeloma

Jingyu Zhu^{1,2,*}, Man Wang^{1,2,*}, Yang Yu³, Huixin Qi⁴, Kunkun Han^{1,2}, Juan Tang^{1,2}, Zubin Zhang^{1,2}, Yuanying Zeng^{1,2}, Biyin Cao^{1,2}, Chunhua Qiao³, Hongjian Zhang⁴, Tingjun Hou^{1,5}, Xinliang Mao^{1,2}

¹Jiangsu Key Laboratory of Translational Research and Therapy for Neuro-psycho-diseases, Department of Pharmacology, College of Pharmaceutical Sciences, Soochow University, Suzhou, China

²Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases, Soochow University, Suzhou, China

³Department of Medicinal Chemistry, College of Pharmaceutical Sciences, Soochow University, Suzhou, China

⁴Department of Pharmaceutical Analysis, College of Pharmaceutical Sciences, Soochow University, Suzhou, China

⁵Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China

*These two authors equally contributed to this study

Published: December 10, 2019

Copyright: Zhu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has been corrected: Due to errors in the final figure composition, the AKT expression from Figure 2A was accidentally duplicated in Figure 4A. The proper Figure 4A and its updated legend are shown below. The authors declare that these corrections do not change the results or conclusions of this paper.

Original article: Oncotarget. 2015; 6:185–195. <https://doi.org/10.18632/oncotarget.2688>




Figure 4: C98 activates apoptotic signaling in MM cells. (A) JJN3 cells were treated with C98 (0, 2.5, 5, 10, 20 μ M) for 24 hr or 10 μ M for 0, 3, 6, or 9 hr, followed by immunoblotting for the expression of p-AKT, t-AKT, pro-caspase-3 (Pro-Casp3), and cleaved caspase-3 (Cle-Casp3). (B) KMS11, LP1, OCI-My5, OPM2, JJN3, and RPMI-8226 were treated with C98 (20 μ M) for 24 hr, followed by immunoblotting for the expression of PARP, Pro-Casp3, and Cle-Casp3. GAPDH was used as a loading control.